氨甲环酸与 COVID-19 中纤溶酶原/纤溶酶惊人的悖论
Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19.
机构信息
Department of Clinical Pharmacology and Medicine, College of Medicine, AL-Mustansiriyiah University, Baghdad, Iraq.
Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Rasheed University College, Baghdad, Iraq.
出版信息
Endocr Metab Immune Disord Drug Targets. 2023;23(1):35-45. doi: 10.2174/1871530322666220801102402.
Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibrinolytic system with the development of coagulopathy. Therefore, modulation of the fibrinolytic system may affect the course of COVID-19. Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity. In addition, TXA has anti-inflammatory, anti-platelet, and anti-thrombotic effects, which may attenuate the COVID-19 severity. Thus, in this narrative review, we try to find the beneficial and harmful effects of TXA in COVID-19.
新型冠状病毒病（COVID-19）是由严重急性呼吸系统综合征，冠状病毒 2 型（SARS-CoV-2）引起的，导致急性组织损伤和过度的免疫反应。在 COVID-19 中，随着凝血功能障碍的发展，纤维蛋白溶解系统发生显著变化。因此，纤维蛋白溶解系统的调节可能会影响 COVID-19 的病程。氨甲环酸（TXA）是一种抗纤维蛋白溶解药物，可减少纤溶酶原转化为纤溶酶，这对于 SARS-CoV-2 的感染性是必需的。此外，TXA 具有抗炎、抗血小板和抗血栓形成的作用，可能减轻 COVID-19 的严重程度。因此，在这篇叙述性综述中，我们试图寻找 TXA 在 COVID-19 中的有益和有害作用。
Zotero 插件